Role of cytolethal distending toxin in altered stool form and bowel phenotypes in a rat model of post-infectious irritable bowel syndrome

Journal of Neurogastroenterology and Motility

Volumn 18, Issue 4, 2012, Pages 434-442

  Pokkunuri, Venkata ^a   Pimentel, Mark ^a   Morales, Walter ^a   Jee, Sam Ryong ^a   Alpern, Joel ^a   Weitsman, Stacy ^a   Marsh, Zachary ^a   Low, Kimberly ^a   Hwang, Laura ^a   Khoshini, Reza ^a   Barlow, Gillian M ^a   Wang, Hanlin ^a   Chang, Christopher ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Animal; Campylobacter infections; Cytolethal distending toxin; Inflammation; Models

Indexed keywords

CYTOLETHAL DISTENDING TOXIN; STEM CELL FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAMPYLOBACTER ENTERITIS; CONTROLLED STUDY; DRY WEIGHT; FECES; INTERSTITIAL CELL OF CAJAL; IRRITABLE COLON; LYMPHOCYTE; NONHUMAN; PHENOTYPE; POSTINFECTIOUS IRRITABLE BOWEL SYNDROME; RAT;

EID: 84872871624     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2012.18.4.434     Document Type: Article

References (46)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):II43-II47.
2. Pimentel M, Hwang L, Melmed GY, et al. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. Dig Dis Sci 2010;55: 145-149.
3. McKendrick MW, Read NW. Irritable bowel syndrome - post salmonella infection. J Infect 1994;29:1-3.
4. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779-782.
5. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44: 400-406.
6. Parry SD, Stansfield R, Jelley D, et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol 2003;98: 327-331.
7. Barber R, Blakey A. Prevalence of gastrointestinal symptoms after bacterial gastroenteritis. Study did not include a control group. BMJ 1997;314:1903.
8. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002;51:410-413.
9. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004;99:1774-1778.
10. Mearin F, Pérez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005;129:98-104.
11. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006;101: 1894-1899.
12. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:535-544.
13. Friedman J NJ, Wegener HC, Tauxe RV. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nachamkin I BM, ed. Campylobacter. 2 ed. Washington: American Society for Microbiology 2000:121-138.
14. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-811.
15. Mead PS, Slutsker L, Griffin PM, Tauxe RV. Food-related illness and death in the United States reply to Dr. Hedberg. Emerg Infect Dis 1999;5:841-842.
16. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 2001;32:1201-1206.
17. Pickett CL, Whitehouse CA. The cytolethal distending toxin family. Trends Microbiol 1999;7:292-297.
18. Lara-Tejero M, Galán JE. CdtA, CdtB, and CdtC form a tripartite complex that is required for cytolethal distending toxin activity. Infect Immun 2001;69:4358-4365.
19. Lara-Tejero M, Galán JE. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein. Science 2000;290: 354-357.
20. Whitehouse CA, Balbo PB, Pesci EC, Cottle DL, Mirabito PM, Pickett CL. Campylobacter jejuni cytolethal distending toxin causes a G2-phase cell cycle block. Infect Immun 1998;66:1934-1940.
21. Hassane DC, Lee RB, Pickett CL. Campylobacter jejuni cytolethal distending toxin promotes DNA repair responses in normal human cells. Infect Immun 2003;71:541-545.
22. Hassane DC, Lee RB, Mendenhall MD, Pickett CL. Cytolethal distending toxin demonstrates genotoxic activity in a yeast model. Infect Immun 2001;69:5752-5759.
23. Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci 2008;53:982-989.
24. Jee SR, Morales W, Low K, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol 2010;16:3680-3686.
25. Morales W, Pimentel M, Hwang L, et al. Acute and chronic histological changes of the small bowel secondary to C. jejuni infection in a rat model for post-infectious IBS. Dig Dis Sci 2011;56:2575-2584.
26. Bercík P, Wang L, Verdú EF, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 2004;127:179-187.
27. Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol 2007;102: 1064-1069.
28. Purdy D, Buswell CM, Hodgson AE, McAlpine K, Henderson I, Leach SA. Characterisation of cytolethal distending toxin (CDT) mutants of Campylobacter jejuni. J Med Microbiol 2000;49:473-479.
29. Chang C, Miller JF. Campylobacter jejuni colonization of mice with limited enteric flora. Infect Immun 2006;74:5261-5271.
30. Fox JG, Rogers AB, Whary MT, et al. Gastroenteritis in NF-kappaB-deficient mice is produced with wild-type Camplyobacter jejuni but not with C. jejuni lacking cytolethal distending toxin despite persistent colonization with both strains. Infect Immun 2004;72: 1116-1125.
31. Gelfanova V, Hansen EJ, Spinola SM. Cytolethal distending toxin of Haemophilus ducreyi induces apoptotic death of Jurkat T cells. Infect Immun 1999;67:6394-6402.
32. Jain D, Prasad KN, Sinha S, Husain N. Differences in virulence attributes between cytolethal distending toxin positive and negative Campylobacter jejuni strains. J Med Microbiol 2008;57:267-272.
33. Hickey TE, McVeigh AL, Scott DA, et al. Campylobacter jejuni cytolethal distending toxin mediates release of interleukin-8 from intestinal epithelial cells. Infect Immun 2000;68:6535-6541.
34. Lara-Tejero M, Galán JE. Cytolethal distending toxin: limited damage as a strategy to modulate cellular functions. Trends Microbiol 2002;10:147-152.
35. Bang DD, Scheutz F, Ahrens P, Pedersen K, Blom J, Madsen M. Prevalence of cytolethal distending toxin (cdt) genes and CDT production in Campylobacter spp. isolated from Danish broilers. J Med Microbiol 2001;50:1087-1094.
36. Dassanayake RP, Zhou Y, Hinkley S, et al. Characterization of cytolethal distending toxin of Campylobacter species isolated from captive macaque monkeys. J Clin Microbiol 2005;43:641-649.
37. Al-Mahmeed A, Senok AC, Ismaeel AY, Bindayna KM, Tabbara KS, Botta GA. Clinical relevance of virulence genes in Campylobacter jejuni isolates in Bahrain. J Med Microbiol 2006;55:839-843.
38. Walker RI, Caldwell MB, Lee EC, Guerry P, Trust TJ, Ruiz-Palacios GM. Pathophysiology of Campylobacter enteritis. Microbiol Rev 1986;50:81-94.
39. Gordon JI. Intestinal epithelial differentiation: new insights from chimeric and transgenic mice. J Cell Biol 1989;108:1187-1194.
40. Ketley JM. Pathogenesis of enteric infection by Campylobacter. Microbiology 1997;143(Pt 1):5-21.
41. Sears CL, Kaper JB. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev 1996;60:167-215.
42. Johnson WM, Lior H. Cytotoxic and cytotonic factors produced by Campylobacter jejuni, Campylobacter coli, and Campylobacter laridis. J Clin Microbiol 1986;24:275-281.
43. Johnson WM, Lior H. A new heat-labile cytolethal distending toxin (CLDT) produced by Campylobacter spp. Microb Pathog 1988;4: 115-126.
44. Jenkins D, Thornley JP, Wright T, et al. Enterochromaffin & mast cell hyperplasia parallels mucosal nerve damage following Campylobacter enteritis [abstract]. Neurogastroenterol Motil 1998;10:464.
45. Oomes PG, Jacobs BC, Hazenberg MP, Bänffer JR, van der Meché FG. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barre syndrome: evidence of molecular mimicry. Ann Neurol 1995; 38:170-175.
46. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651-1659.